Nomocan Pharmaceuticals

Developing first-in-class targeted monoclonal antibody therapies for aggressive cancers

placeNew York City, New York, United States calendar_todayFounded 2014 groups4 employees language nomocan.com

Nomocan Pharmaceuticals Llc

Reg. No. 462209185United States

2 investors on record.

Investor type	Count	Share
Venture capital	2	100%

Coming soon